Walmart has agreed to pay $50 million to resolve a lawsuit brought by the U.S. government accusing the retailer of improperly dispensing opioid prescriptions, the Department of Justice announced on Friday. The settlement addresses allegations that Walmart pharmacies violated the Controlled Substances Act by failing to identify and report suspicious opioid prescriptions, contributing to the nationwide opioid crisis.
The lawsuit, which was initiated in December 2020, claimed that Walmart repeatedly missed warning signs of unlawful prescribing practices dating back to 2013. Federal prosecutors accused some Walmart compliance officials of knowing that certain prescribers operated “pill mills” — clinics or practitioners that distributed opioids irresponsibly — yet still filled prescriptions issued by those individuals. The case represented one of the Justice Department’s most significant efforts to hold a single company accountable for its role in the opioid epidemic.
Under the terms of the settlement, Walmart will not acknowledge liability. In a recent regulatory filing, the company described the $50 million payment as “immaterial” relative to its financial performance, noting a net income of $11.7 billion in the six months ending July 31. Along with the monetary settlement, Walmart has agreed to implement stricter oversight measures for pharmacists and establish a hotline for employees and consumers to report suspected illegal dispensing activities.
Associate Attorney General Stanley Woodward emphasized the commitment of the Justice Department to prioritizing public health in the ongoing fight against opioid misuse. The settlement was formally filed in federal court in Wilmington, Delaware, on Thursday.
This resolution follows a previous $3.1 billion agreement Walmart reached in 2022 with state and local governments addressing similar claims tied to the opioid crisis. The U.S. Centers for Disease Control and Prevention reports that more than 905,000 Americans died from opioid overdoses between 1999 and 2025, though annual death rates have begun to decline since 2022.
Other notable legal actions targeting opioid manufacturers and distributors have included Purdue Pharma, which pleaded guilty to criminal charges in 2020 related to its sale of OxyContin following bankruptcy proceedings, and the drug wholesaler Cencora (formerly AmerisourceBergen).
In March 2024, U.S. District Judge Colm Connolly narrowed the scope of the government’s lawsuit against Walmart, dismissing allegations that the company failed to report suspicious prescriptions to the Drug Enforcement Administration and that pharmacists did not document red flags. However, the judge allowed claims that Walmart’s compliance personnel knowingly approved invalid prescriptions and that pharmacists dispensed prescriptions they suspected were invalid to move forward.
Walmart responded to the settlement by expressing satisfaction with resolving the matter and reaffirming its support for the work performed by its pharmacists in patient care.